Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 6Genitourinary 3Tumor-Agnostic 1Thoracic 1Gynecologic 1

Conditions

Ovarian Neoplasms 8Fallopian Tube Neoplasms 3Carcinoma, Ovarian Epithelial 2Uterine Cervical Neoplasms 1Recurrent Uterine Sarcoma 1Neoplasms 1Carcinoma 1

Interventions

Paclitaxel 7Cisplatin 6pembrolizumab 5Carboplatin 5Bevacizumab 5liposomal doxorubicin 3Gemcitabine 3trebananib 2niraparib 2interferon gamma-1b 2dostarlimab 2catumaxomab 2atezolizumab 2anlotinib 2Topotecan 2Radiotherapy, Intensity-Modulated 2Ocoxin 2Itraconazole 2Injections 2Hyperthermic Intraperitoneal Chemotherapy 2Drug Therapy 2Docetaxel 2vosaroxin 1vistusertib 1pertuzumab 1peginterferon alfa-2b 1olaparib 1nintedanib 1lanreotide 1epothilone B 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × Sorafenib × Gynecologic × Clear all
NCT00510250 2015-07-27

A Phase I/II Study of Cisplatin and Radiation in Combination With Sorafenib in Cervical Cancer

University Health Network, Toronto

Phase 1/2 Completed
13 enrolled
Gynecologic

Carcinoma, Uterine Cervical Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡